Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Common Variant Burden Contributes to the Familial Aggregation of Migraine in 1,589 Families.

Gormley P, Kurki MI, Hiekkala ME, Veerapen K, Häppölä P, Mitchell AA, Lal D, Palta P, Surakka I, Kaunisto MA, Hämäläinen E, Vepsäläinen S, Havanka H, Harno H, Ilmavirta M, Nissilä M, Säkö E, Sumelahti ML, Liukkonen J, Sillanpää M, Metsähonkala L, Koskinen S, Lehtimäki T, Raitakari O, Männikkö M, Ran C, Belin AC, Jousilahti P, Anttila V, Salomaa V, Artto V, Färkkilä M; 23andMe Research Team; International Headache Genetics Consortium (IHGC), Runz H, Daly MJ, Neale BM, Ripatti S, Kallela M, Wessman M, Palotie A.

Neuron. 2018 May 16;98(4):743-753.e4. doi: 10.1016/j.neuron.2018.04.014. Epub 2018 May 3.

PMID:
29731251
2.

Painful musculosceletal disorders and depression among working aged migraineurs.

Sumelahti ML, Mattila K, Sumanen M.

Acta Neurol Scand. 2018 Jul;138(1):93-98. doi: 10.1111/ane.12919. Epub 2018 Mar 14.

PMID:
29542115
3.

Evaluation of serum miR-191-5p, miR-24-3p, miR-128-3p, and miR-376c-3 in multiple sclerosis patients.

Vistbakka J, Sumelahti ML, Lehtimäki T, Elovaara I, Hagman S.

Acta Neurol Scand. 2018 Mar 12. doi: 10.1111/ane.12921. [Epub ahead of print]

PMID:
29527713
4.

The contribution of CACNA1A, ATP1A2 and SCN1A mutations in hemiplegic migraine: A clinical and genetic study in Finnish migraine families.

Hiekkala ME, Vuola P, Artto V, Häppölä P, Häppölä E, Vepsäläinen S, Cuenca-León E, Lal D, Gormley P, Hämäläinen E, Ilmavirta M, Nissilä M, Säkö E, Sumelahti ML, Harno H, Havanka H, Keski-Säntti P, Färkkilä M, Palotie A, Wessman M, Kaunisto MA, Kallela M.

Cephalalgia. 2018 Jan 1:333102418761041. doi: 10.1177/0333102418761041. [Epub ahead of print]

PMID:
29486580
5.

Common comorbidities and survival in MS: Risk for stroke, type 1 diabetes and infections.

Murtonen A, Kurki S, Hänninen K, Soilu-Hänninen M, Sumelahti ML.

Mult Scler Relat Disord. 2018 Jan;19:109-114. doi: 10.1016/j.msard.2017.10.019. Epub 2017 Nov 13.

PMID:
29190573
6.

Medical students' experience of emotions and success in neurological studies - What do they tell us?

Ansakorpi H, Sumelahti ML, Kaasila R.

BMC Med Educ. 2017 Apr 4;17(1):68. doi: 10.1186/s12909-017-0905-4.

7.

Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis.

Soini E, Joutseno J, Sumelahti ML.

Clin Ther. 2017 Mar;39(3):537-557.e10. doi: 10.1016/j.clinthera.2017.01.028. Epub 2017 Feb 14.

8.

Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness.

Järvinen E, Holmberg M, Sumelahti ML.

Neurol Int. 2016 Sep 30;8(3):6513. eCollection 2016 Sep 30.

9.

Risk of osteoporotic fractures in multiple sclerosis patients in southwest Finland.

Åivo J, Kurki S, Sumelahti ML, Hänninen K, Ruutiainen J, Soilu-Hänninen M.

Acta Neurol Scand. 2017 May;135(5):516-521. doi: 10.1111/ane.12623. Epub 2016 Jun 22.

PMID:
27334254
10.

[Update on Current Care Guideline: Multiple sclerosis].

Remes A, Airas L, Atula S, Färkkilä M, Hartikainen P, Koivisto K, Mäenpää E, Ruutiainen J, Sumelahti ML; Päivitystiivistelmä.

Duodecim. 2015;131(5):500-1. Finnish.

PMID:
26237913
11.

Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up.

Sumelahti ML, Holmberg MH, Murtonen A, Huhtala H, Elovaara I.

Mult Scler Int. 2014;2014:186950. doi: 10.1155/2014/186950. Epub 2014 Nov 9.

12.

Modelling the Persistence of Disease-Modifying Drug Treatment (DMT) and its Independent Drivers in Finnish Multiple Sclerosis (MS) Patients: Parametric Survival Modelling.

Soini E, Holmberg M, Asseburg C, Sumelahti ML.

Value Health. 2014 Nov;17(7):A400. doi: 10.1016/j.jval.2014.08.911. Epub 2014 Oct 26. No abstract available.

13.

Cost-Utility Analysis (cua) Of First-Line Disease-Modifying Treatments (DMT) Versus Best Supportive Care (Bsc) In Finnish Relapsing-Remitting Multiple Sclerosis (RRMS) Patients.

Soini E, Asseburg C, Sumelahti ML.

Value Health. 2014 Nov;17(7):A399. doi: 10.1016/j.jval.2014.08.906. Epub 2014 Oct 26. No abstract available.

14.

Increased Female MS Incidence and Differences in Gender-Specific Risk in Medium- and High-Risk Regions in Finland from 1981-2010.

Holmberg M, Murtonen A, Elovaara I, Sumelahti ML.

Mult Scler Int. 2013;2013:182516. doi: 10.1155/2013/182516. Epub 2013 Nov 10. Review.

15.

[Woman, hormones and migraine].

Sumelahti ML.

Duodecim. 2013;129(4):345-50. Review. Finnish.

PMID:
23484351
16.

A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.

Soilu-Hänninen M, Aivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä M, Tienari P, Atula S, Sarasoja T, Herrala L, Keskinarkaus I, Kruger J, Kallio T, Rocca MA, Filippi M.

J Neurol Neurosurg Psychiatry. 2012 May;83(5):565-71. doi: 10.1136/jnnp-2011-301876. Epub 2012 Feb 22.

PMID:
22362918
17.

Prescription patterns in preventive and abortive migraine medication.

Sumelahti ML, Mattila K, Sillanmäki L, Sumanen M.

Cephalalgia. 2011 Dec;31(16):1659-63. doi: 10.1177/0333102411427602. Epub 2011 Nov 24.

PMID:
22116941
18.

Causes of death among patients with multiple sclerosis.

Sumelahti ML, Hakama M, Elovaara I, Pukkala E.

Mult Scler. 2010 Dec;16(12):1437-42. doi: 10.1177/1352458510379244. Epub 2010 Sep 8.

PMID:
20826526
19.

A visual migraine aura locus maps to 9q21-q22.

Tikka-Kleemola P, Artto V, Vepsäläinen S, Sobel EM, Räty S, Kaunisto MA, Anttila V, Hämäläinen E, Sumelahti ML, Ilmavirta M, Färkkilä M, Kallela M, Palotie A, Wessman M.

Neurology. 2010 Apr 13;74(15):1171-7. doi: 10.1212/WNL.0b013e3181d8ffcb.

20.

Genome-wide association study in a high-risk isolate for multiple sclerosis reveals associated variants in STAT3 gene.

Jakkula E, Leppä V, Sulonen AM, Varilo T, Kallio S, Kemppinen A, Purcell S, Koivisto K, Tienari P, Sumelahti ML, Elovaara I, Pirttilä T, Reunanen M, Aromaa A, Oturai AB, Søndergaard HB, Harbo HF, Mero IL, Gabriel SB, Mirel DB, Hauser SL, Kappos L, Polman C, De Jager PL, Hafler DA, Daly MJ, Palotie A, Saarela J, Peltonen L.

Am J Hum Genet. 2010 Feb 12;86(2):285-91. doi: 10.1016/j.ajhg.2010.01.017.

Supplemental Content

Loading ...
Support Center